VRNA - Verona Pharma plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.25
-0.75 (-10.71%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.00
Open6.65
Bid5.50 x 1400
Ask19.00 x 1300
Day's Range6.22 - 7.00
52 Week Range5.65 - 25.55
Volume10,492
Avg. Volume10,395
Market Cap87.954M
Beta (3Y Monthly)-0.61
PE Ratio (TTM)N/A
EPS (TTM)-2.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.80
Trade prices are not sourced from all markets
  • Verona Pharma Enters Oversold Territory
    Zacks2 days ago

    Verona Pharma Enters Oversold Territory

    Verona Pharma PLC American Depositary Share (VRNA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire5 days ago

    Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

    LAMA/LABA therapies are commonly used in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (“COPD”). Patients already receiving inhaled corticosteroid (“ICS”) therapy were allowed to continue to receive a stable dose of ICS throughout the study, thus providing additional data on “triple therapy” use.

  • Verona Pharma Sees Hammer Chart Pattern: Time to Buy?
    Zacks7 days ago

    Verona Pharma Sees Hammer Chart Pattern: Time to Buy?

    Verona Pharma has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswire9 days ago

    Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that the World Health Organization (“WHO”) approved “ensifentrine” as the recommended International Non-proprietary Name (“INN”) for the company’s drug candidate, RPL554. Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have bronchodilator as well as anti-inflammatory properties, and is currently in development for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”), cystic fibrosis (“CF”) and potentially asthma.

  • GlobeNewswire16 days ago

    Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces the expansion of its global clinical development team with the appointment of Kathleen Rickard, MD, as Chief Medical Officer, and Tara Rheault, PhD, MPH, as Vice President of Research and Development Operations and Global Project Management. Drs. Rickard and Rheault will be based in the Company’s U.S. offices from where they will leverage their expertise to help drive global R&D activities.

  • GlobeNewswirelast month

    Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (“PK”) profile, efficacy and safety of a dry powder inhaler (“DPI”) formulation of RPL554 in patients with moderate to severe chronic obstructive pulmonary disease (“COPD”).

  • GlobeNewswire2 months ago

    Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018

    Initiated a Phase 2 trial of RPL554 as add-on to dual bronchodilator therapy for COPD maintenance treatment; enrolled last patient and dosing underway Progressed DPI and pMDI.

  • GlobeNewswire3 months ago

    Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that is has enrolled the last patient in its Phase 2 clinical trial evaluating the effect of nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic / long-acting beta2-agonists (“LAMA/LABA”) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (“COPD”). A total of 79 patients with COPD have enrolled at sites in the U.S. and in the UK in this three way crossover study.

  • GlobeNewswire6 months ago

    Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

    LONDON, Aug. 01, 2018 (GLOBE NEWSWIRE) --  Verona Pharma plc (VRP.L) (VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces the initiation of a Phase 2 clinical trial evaluating the effect of nebulized RPL554 as an add-on to treatment with dual long-acting anti-muscarinic / long-acting beta2-agonist drugs ("LAMA/LABA"), which are commonly used in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease ("COPD"). The first patients have been enrolled and dosed in the study, and top line data are expected in the first quarter of 2019.

  • GlobeNewswire6 months ago

    Verona Pharma plc : Notice of Results

    Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development Update LONDON, July 26, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ...

  • GlobeNewswire6 months ago

    Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference

    LONDON, July 24, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative ...

  • GlobeNewswire7 months ago

    Verona Pharma plc : Result of General Meeting of Shareholders

    LONDON, June 26, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of ...